ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) is 4.43% higher on its value in year-to-date trading and has touched a low of $0.35 and a high of $8.18 in the current 52-week trading range. The ASLN stock was last observed hovering at around $2.12 in the last trading session, with the day’s gains setting it 0.07% off its average median price target of $5.50 for the next 12 months. It is also 63.56% off the consensus price target high of $6.01 offered by 3 analysts, but current levels are 56.2% higher than the price target low of $5.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $2.19, the stock is 16.77% and 24.39% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.6 million and changing 3.50% at the moment leaves the stock 22.35% off its SMA200. ASLN registered -39.08% loss for a year compared to 6-month loss of -10.55%. The firm has a 50-day simple moving average (SMA 50) of $1.8111 and a 200-day simple moving average (SMA200) of $1.8407.
The stock witnessed a 20.45% gain in the last 1 month and extending the period to 3 months gives it a 81.20%, and is 13.98% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.71% over the week and 8.75% over the month.
Distance from 52-week low is 526.94% and -73.17% from its 52-week high.
ASLAN Pharmaceuticals Limited (ASLN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ASLAN Pharmaceuticals Limited (ASLN) is a “Overweight”. 3 analysts offering their recommendations for the stock have an average rating of 2.30, where 1 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ASLAN Pharmaceuticals Limited is expected to release its quarterly report on 08/10/2020 and quarterly earnings per share for the current quarter are estimated at -$0.07.The EPS is expected to grow by 80.70% this year.
ASLAN Pharmaceuticals Limited (ASLN) Top Institutional Holders
16 institutions hold shares in ASLAN Pharmaceuticals Limited (ASLN), with institutional investors hold 8.68% of the company’s shares. The shares outstanding are 37.99M, and float is at 36.90M with Short Float at 0.03%. Institutions hold 8.68% of the Float.
The top institutional shareholder in the company is Temasek Holdings (Private) Limited with over 1.42 million shares valued at $1.45 million. The investor’s holdings represent 18.97% of the ASLN Shares outstanding. As of Mar 30, 2020, the second largest holder is Sio Capital Management, LLC with 1.29 million shares valued at $1.32 million to account for 17.27% of the shares outstanding. The other top investors are Platinum Investment Management Ltd which holds 0.42 million shares representing 5.54% and valued at over $0.42 million, while DAFNA Capital Management, LLC holds 1.15% of the shares totaling 86082.0 with a market value of $87803.0.